Literature DB >> 20921312

Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis.

Catharine C Bulik1, Dora E Wiskirchen, Ashley Shepard, Christina A Sutherland, Joseph L Kuti, David P Nicolau.   

Abstract

Tissue penetration of systemic antibiotics is an important consideration for positive outcomes in diabetic patients. Herein we describe the exposure profile and penetration of tigecycline in the interstitial fluid of wound margins versus that of uninfected thigh tissue in 8 adult diabetic patients intravenously (IV) administered 100 mg and then 50 mg of tigecycline twice daily for 3 to 5 doses. Prior to administration of the first dose, 2 microdialysis catheters were inserted into the subcutaneous tissue, the first within 10 cm of the wound margin and the second in the thigh of the same extremity. Samples for determination of plasma and tissue concentrations were simultaneously collected over 12 h under steady-state conditions. Tissue concentrations were corrected for percent in vivo recovery by the retrodialysis technique. Plasma samples were also collected for determination of protein binding at 1, 6, and 12 h postdose for each patient. Protein binding data were corrected using a fitted polynomial equation. The mean patient weight was 95.1 kg (range, 63.6 to 149.2 kg), the mean patient age was 63.5 ± 9.4 years, and 75% of the patients were males. The mean values for the plasma, thigh, and wound free area under the concentration-time curve from 0 to 24 h (fAUC(0-24)) were 2.65 ± 0.33, 2.52 ± 1.15, and 2.60 ± 1.02 μg·h/ml, respectively. Protein binding was nonlinear, with the percentage of free drug increasing with decreasing serum concentrations. Exposure values for thigh tissue and wound tissue were similar (P = 0.986). Mean steady-state tissue concentrations for the thigh and wound were similar at 0.12 ± 0.02 μg/ml, and clearance from the tissues appeared similar to that from plasma. Tissue penetration ratios (tissue fAUC/plasma fAUC) were 99% in the thigh and 100% in the wound (P = 0.964). Tigecycline penetrated equally well into wound and uninfected tissue of the same extremity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20921312      PMCID: PMC2981255          DOI: 10.1128/AAC.01051-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Diagnosis and treatment of diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; H Gunner Deery; John M Embil; Warren S Joseph; Adolf W Karchmer; Jack L LeFrock; Daniel P Lew; Jon T Mader; Carl Norden; James S Tan
Journal:  Clin Infect Dis       Date:  2004-09-10       Impact factor: 9.079

2.  Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors:  Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

3.  Incidence, outcomes, and cost of foot ulcers in patients with diabetes.

Authors:  S D Ramsey; K Newton; D Blough; D K McCulloch; N Sandhu; G E Reiber; E H Wagner
Journal:  Diabetes Care       Date:  1999-03       Impact factor: 19.112

4.  Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations.

Authors:  Heather K Sun; Christine T Ong; Ambreen Umer; Dawn Harper; Steven Troy; Charles H Nightingale; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Quantitation of tigecycline, a novel glycylcycline [corrected] by liquid chromatography.

Authors:  Chonghua Li; Christina A Sutherland; Charles H Nightingale; David P Nicolau
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2004-11-25       Impact factor: 3.205

6.  Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.

Authors:  M Müller; O Haag; T Burgdorff; A Georgopoulos; W Weninger; B Jansen; G Stanek; H Pehamberger; E Agneter; H G Eichler
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

7.  Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.

Authors:  Michael J Dowzicky; Choong H Park
Journal:  Clin Ther       Date:  2008-11       Impact factor: 3.393

Review 8.  Diagnosing and treating diabetic foot infections.

Authors:  Benjamin A Lipsky; Anthony R Berendt; John Embil; Fausto De Lalla
Journal:  Diabetes Metab Res Rev       Date:  2004 May-Jun       Impact factor: 4.876

9.  Medical treatment of diabetic foot infections.

Authors:  Benjamin A Lipsky
Journal:  Clin Infect Dis       Date:  2004-08-01       Impact factor: 9.079

10.  Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model.

Authors:  Jared L Crandon; Mary Anne Banevicius; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

View more
  16 in total

Review 1.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

2.  Eravacycline Pharmacokinetics and Challenges in Defining Humanized Exposure In Vivo.

Authors:  Abrar K Thabit; Marguerite L Monogue; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 3.  Nonlinear Protein Binding: Not What You Think.

Authors:  Amelia N Deitchman; Ravi Shankar Prasad Singh; Hartmut Derendorf
Journal:  J Pharm Sci       Date:  2018-04-04       Impact factor: 3.534

Review 4.  Protein binding: do we ever learn?

Authors:  Markus A Zeitlinger; Hartmut Derendorf; Johan W Mouton; Otto Cars; William A Craig; David Andes; Ursula Theuretzbacher
Journal:  Antimicrob Agents Chemother       Date:  2011-05-02       Impact factor: 5.191

5.  Determination of tissue penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis.

Authors:  Dora E Wiskirchen; Ashley Shepard; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 6.  A comprehensive review on the pharmacokinetics of antibiotics in interstitial fluid spaces in humans: implications on dosing and clinical pharmacokinetic monitoring.

Authors:  Tony K L Kiang; Urs O Häfeli; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2014-08       Impact factor: 6.447

7.  In Vitro Pharmacodynamics of Vancomycin against Methicillin-Susceptible and -Resistant Staphylococcus aureus: Considering the Variability in Observed Tissue Exposure.

Authors:  Yukihiro Hamada; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-11-30       Impact factor: 5.191

8.  Tissue pharmacokinetics of cefazolin in patients with lower limb infections.

Authors:  Amira A Bhalodi; Seth T Housman; Ashley Shepard; James Nugent; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

9.  Pharmacokinetics and Tissue Penetration of Ceftolozane-Tazobactam in Diabetic Patients with Lower Limb Infections and Healthy Adult Volunteers.

Authors:  Marguerite L Monogue; Sean M Stainton; Arlinda Baummer-Carr; Ashley K Shepard; James F Nugent; Joseph L Kuti; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

10.  Monte Carlo simulation evaluation of tigecycline dosing for bacteria with raised minimum inhibitory concentrations in non-critically ill adults.

Authors:  Brianna Kispal; Sandra A N Walker
Journal:  Eur J Clin Pharmacol       Date:  2020-09-25       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.